Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer

2017 ◽  
Vol 27 (7) ◽  
pp. 1343-1349 ◽  
Author(s):  
Zhen Yan ◽  
Xiaoyu Tian ◽  
Ruifang Wang ◽  
Xiaolin Cheng ◽  
Jianqiang Mi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Tumor ◽  
Clinical Characteristics ◽  
Transforming Growth Factor ◽  
Cox Regression ◽  
Figo Stage ◽  
Start Time ◽  
Benign Ovarian Tumor ◽  
Tgf Β1

ObjectiveThis study aimed to evaluate the prognosis significance of zinc-finger E-box binding homeobox 2 (ZEB2) and transforming growth factor β1 (TGF-β1) as well as other clinical characteristics in epithelial ovarian cancer (EOC).MethodsThis retrospective study examined the expressions of ZEB2 and TGF-β1 in 64 EOC specimens, 36 benign ovarian tumor specimens, and 28 normal ovarian specimens by immunohistochemistry. The correlation of the expressions of ZEB2 and TGF-β1 was analyzed by the Spearman rank correlation analysis. The Kaplan-Meier method was used to construct crude survival curves, and the prognostic roles of ZEB2 and TGF-β1 as well as clinical characteristics were evaluated by Cox proportional hazards regression analysis.ResultsThe positive expression rates of ZEB2 and TGF-β1 were increased in EOC specimens compared with benign ovarian tumor and normal ovary specimens (P < 0.05), and ZEB2 expression was positively correlated with TGF-β1 expression (r = 0.538, P = 0.000). In addition, the overall survival rate of EOC patients was associated with the expressions of ZEB2 and TGF-β1, age, differentiated grade, International Federation of Gynecology and Obstetrics (FIGO) stage, preoperative serum CA125 level, postoperative start time of chemotherapy, and treatment course (all P < 0.05). Multivariate Cox regression demonstrated that FIGO stage (P = 0.033), TGF-β1 expression (P = 0.043), postoperative start time of chemotherapy (P = 0.009), and treatment course (P = 0.000) were prognostic factors for EOC.ConclusionsZEB2 and TGF-β1 may promote EOC progression, and FIGO stage, TGF-β1 expression, postoperative start time of chemotherapy, and treatment course may be associated with the prognosis of EOC.

scholarly journals Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study

2020 ◽  
Vol Volume 12 ◽  
pp. 637-649 ◽  
Author(s):  
Chen-Yu Huang ◽  
Wen-Hsun Chang ◽  
Hsin-Yi Huang ◽  
Chao-Yu Guo ◽  
Yiing-Jenq Chou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Tumor ◽  
Subsequent Development ◽  
Population Based ◽  
Benign Ovarian Tumor ◽  
Ovarian Surgery

scholarly journals Tumor-associated macrophages mediate immune suppression by secreting PD-L1+ exosomes in epithelial ovarian cancer

2019 ◽  
Author(s):  
Xingchen Zhou ◽  
Xiaoli Wu ◽  
Xiaoduan Li ◽  
Yi Zhang ◽  
Xipeng Wang
Keyword(s):  
Ovarian Cancer ◽  
T Cells ◽  
T Cell ◽  
Epithelial Ovarian Cancer ◽  
Signaling Pathway ◽  
Immune Suppression ◽  
Ovarian Tumor ◽  
Tumor Associated Macrophages ◽  
Programmed Death ◽  
Benign Ovarian Tumor

Abstract Purpose: To study the role of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) signaling pathway in patients with epithelial ovarian cancer (EOC). Methods: A total of 10 EOC specimens and 10 benign ovarian tumor were obtained from surgery and the pathological type. We used the methods of immunofluorescence confocal microscopy, western blot, MTT assay, apoptosis detection and co-culture to verify the aim of the research. Results: In the present study, it was validated that the number of PD-L1+ tumor-associated macrophages (TAMs) per field was significantly increased in EOC tissues compared with benign ovarian tumor tissues. Furthermore, it was demonstrated that PD-L1 was expressed on the membrane of TAM-derived exosomes, which may inhibit the proliferation and induce the apoptosis of T cells by activating the caspase 3 signaling pathway. The analysis of the supernatant of T cells co-cultured with TAM drived exosome revealed that the levels of pro-inflammatory cytokines and tumor necrosis factor α decreased compared with those T cells co-cultured with monocyte drived exosome. However, the expression of the immuno-suppressive cytokine, interleukin 10 and markers of T cell exhaustion (the inhibitory molecule lymphocyte activated gene-3, T-cell immunoglobulin and mucin domain-containing protein-3 and PD-1) increased. Conclusions: The present study demonstrated that the M2-derived exosomes regulate immune suppression in the EOC microenvironment. The findings of the present study provide a theoretical basis for future target therapy on exosomes from immune cells to treat EOC.

scholarly journals Serum Levels of S100A11 and MMP-9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Wenjing Li ◽  
Zhumei Cui ◽  
Yan Kong ◽  
Xiangyu Liu ◽  
Xiangyu Wang
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Significance ◽  
Ovarian Tumor ◽  
Tumor Staging ◽  
Serum Levels ◽  
Clinicopathological Characteristics ◽  
Chemotherapy Response ◽  
Healthy Women ◽  
Benign Ovarian Tumor

Objective. To investigate the serum levels of calgizzarin (S100A11) and matrix metalloproteinase-9 (MMP9) in patients with epithelial ovarian cancer (EOC) and determine their clinical significance. Methods. Serum levels of S100A11 and MMP9 were detected in patients with EOC, patients with benign ovarian tumor, and healthy women. The correlation between the two markers and clinicopathological characteristics of ovarian cancer was analysed. Results. The serum levels of S100A11 and MMP-9 in patients with EOC were higher than those in patients with benign ovarian tumor and in healthy women, and the expression levels of S100A11 and MMP-9 were positively correlated. S100A11 and MMP-9 were correlated with tumor staging, postoperative residual foci, ascites volume, serum CA125 level, chemotherapy response, and lymph node metastasis, while S100A11 and MMP-9 were not associated with the bilevel classification, histological type, age, and degree of differentiation. Conclusion. S100A11 and MMP-9 were both highly expressed in the serum of patients with EOC and were associated with cancer development, invasion, and metastasis. Therefore, they can be used as an important reference maker in the diagnosis and treatment of ovarian cancer.

scholarly journals High expression of junctional adhesion molecule-A is associated with poor survival in patients with epithelial ovarian cancer

2019 ◽  
Vol 34 (3) ◽  
pp. 262-268 ◽  
Author(s):  
Boljevic Ivana ◽  
Malisic Emina ◽  
Milovic-Kovacevic Marijana ◽  
Jovanic Irena ◽  
Bukumiric Zoran ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Overall Survival ◽  
Regression Analysis ◽  
Epithelial Ovarian Cancer ◽  
Adhesion Molecule ◽  
Cox Regression ◽  
Figo Stage ◽  
Cox Regression Analysis ◽  
Kaplan Meier

Purpose: Aberrant expression of different tight junction proteins, including the junctional adhesion molecule-A (JAM-A), has been frequently reported in association with tumor progression of several malignancies. To our knowledge, this is the first study examining the clinical significance of JAM-A gene expression in epithelial ovarian cancer. Methods: JAM-A expression levels in 44 epithelial ovarian cancer and 12 benign formalin-fixed paraffin-embedded samples were determined by reverse transcription quantitative polymerase chain reaction. Receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic and prognostic potential of JAM-A. Associations between JAM-A expression and clinicopathological characteristics of epithelial ovarian cancer were analyzed using Fisher’s exact test. The Kaplan–Meier method and univariate Cox regression analysis were used for the survival analysis. P ⩽ 0.05 was considered statistically significant. Results: ROC curve analyses showed that JAM-A gene expression exhibits both diagnostic and prognostic performance in epithelial ovarian cancer (area under the curve (AUC) 0.640, 95% confidence interval (CI) 0.488, 0.792, sensitivity 43.18%, specificity 100% and AUC 0.621, 95% CI 0.427, 0.816, sensitivity 52.63%, specificity 85%, respectively). JAM-A expression was significantly associated with International Federation of Gynecologists and Obstetricians (FIGO) stage ( P =0.049) and the Kaplan–Meier method demonstrated that patients with high expression of JAM-A had significantly worse overall survival compared to patients with low JAM-A expression ( P =0.004). Moreover, univariate Cox regression analysis showed that FIGO stage, peritoneal metastasis, residual tumor and JAM-A expression were significantly associated with reduced overall survival in epithelial ovarian cancer. Conclusions: Our results indicate that high levels of JAM-A expression are associated with an advanced clinicopathological feature and may have diagnostic potential; also, it could be a predictor of poor overall survival in patients with epithelial ovarian cancer.

scholarly journals Evaluating the Association between Clinical Characteristics with Progression-Free Survival and 3-Year Survival in Patients with Epithelial Ovarian Cancer

2021 ◽  
Vol 15 (4) ◽  
pp. 162
Author(s):  
Brahmana Askandar Tjokroprawiro ◽  
Sonny Fadli ◽  
Budiono Budiono
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Characteristics ◽  
Cox Regression ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Disease Recurrence ◽  
P Value ◽  
Free Survival ◽  
Hazard Ratios

Background: This study was conducted to determine the association between clinical characteristics, progression-free survival (PFS), and 3-year survival in patients with epithelial ovarian cancer who underwent surgery in 2016-2017 at RSUD Dr. Soetomo. This study was carried out with the hope of contributing to services for patients with epithelial ovarian cancer to improve outcomes at RSUD Dr. Soetomo. Methods: This retrospective analytic study used medical record data. Survival analysis was done employing Kaplan-Meier and log-rank tests, while Cox regression was utilized to analyze characteristics, recurrence, and mortality. Results: In 2016-2017, 56 patients with epithelial ovarian cancer met the inclusion criteria. Clinical characteristics of residue, stage had significant associations with PFS (P-value of 0.007 and P-value of 0.005, respectively). Residue, stage, histopathology, and the number of chemotherapy cycles had significant associations with 3-year survival (P-value of 0.001, P-value of < 0.001, P-value of < 0.001, P-value of 0.031, respectively). Recurrence and stage had a significant association with the following hazard ratios: stage I HR: 1 (CI 95%, P-value 0.145), stage II HR: 6.5 (CI 95% 0.6–74.7, P-value 0.134), stage III HR: 12.2 (CI 95% 1.4–105.4, P-value 0.061), and stage IV HR: 10.4 (CI 95% 0.8–120.8, P-value 0.061). Mortality had significant associations with stage, histopathology, and the number of chemotherapy cycles, with hazard ratios as follows: stage IV HR: 43.6 (CI 95% 4.5–417.9, P-value 0.001), seromucinous histopathology HR: 20.1 (CI 95% 0.9–408.6, P-value 0.026), chemotherapy cycles < 3 HR: 3.6 (CI 95% 1.2–11.5, P-value 0.459), and > 3 HR: 1 (CI 95%, P-value 0.028).Conclusions: Residue and stage had statistically significant associations with PFS and can be predictors for disease recurrence. Residue, stage, histopathology, number of chemotherapy cycles had significant associations with 3-year survival, but only the latter three characteristics can be predictors for mortality

ErbB-3 Predicts Survival in Ovarian Cancer

2006 ◽  
Vol 24 (26) ◽  
pp. 4317-4323 ◽  
Author(s):  
Berno Tanner ◽  
Dirk Hasenclever ◽  
Katja Stern ◽  
Wiebke Schormann ◽  
Martin Bezler ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Time ◽  
Cox Regression ◽  
Figo Stage ◽  
Hazard Ratio ◽  
Gynecology And Obstetrics ◽  
Her3 Expression ◽  
Primary Epithelial Ovarian Cancer ◽  
Egfr Family

Background HER3 (erbB-3) is a member of the epidermal growth factor receptor (EGFR) family. After dimerization with other members of the EGFR family several signal transduction cascades can be activated, including phosphoinosite 3′-kinase (PI3-K)/Akt and extracellular signal-regulated kinase (ERK1/2). Here, we studied a possible association between HER3 expression and prognosis in patients with ovarian cancer. Methods Tumor tissue of 116 consecutive patients diagnosed with primary epithelial ovarian cancer between 1986 and 1995 was analyzed immunohistochemically for HER3 expression. A possible influence of HER3 expression on survival was studied by multivariate Cox regression adjusting for established clinical prognostic factors. Results A positive HER3 expression was observed in 53.4% of the patients. HER3 expression was associated with decreased survival in proportional hazard modeling, including the International Federation of Gynecology and Obstetrics (FIGO) stage, histologic grade and type, residual disease, and age. After likelihood ratio forward as well as backward selection, only HER3 expression (hazard ratio, 1.71; 95% CI, 1.10 to 2.67; P = .018), FIGO stage (hazard ratio, 4.78; 95% CI, 1.89 to 12.08; P = .001), residual tumor (hazard ratio, 2.69; 95% CI, 1.40 to 5.17; P = .003), and age (hazard ratio, 2.06; 95% CI, 1.17 to 3.65; P = .013) were found to be significant. Kaplan-Meier plots demonstrated a clear influence of HER3 expression on survival time. Median survival time was 3.31 years (95% CI, 1.93 to 4.68) for patients with low HER3 expression, compared with only 1.80 years (95% CI, 0.83 to 2.78) for patients with HER3 overexpression (log-rank test P = .0034). Conclusion HER3 may represent a new prognostic factor in primary epithelial ovarian cancer. Pending validation, exploration of therapeutic strategies to block HER3 could be warranted.

scholarly journals A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer

2016 ◽  
Vol 27 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Tao Zhu ◽  
Wen Gao ◽  
Xi Chen ◽  
Ying Zhang ◽  
Meijuan Wu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Ovarian Tumor ◽  
Patient Survival ◽  
Chain Reaction ◽  
Tumor Patients ◽  
Serum Mirna ◽  
Benign Ovarian Tumor ◽  
Polymerase Chain

ObjectiveEarly diagnosis of epithelial ovarian cancer is critical for patient survival. The objective of this pilot study is to identify a circulating micro (mi)RNA as a potential biomarker for epithelial ovarian cancer.MethodsA total of 135 epithelial ovarian cancer patients and 54 benign ovarian tumor patients were recruited for this study. Using customized TaqMan low density miRNA arrays, we first screened expression levels of 48 miRNAs in sera from 18 epithelial ovarian cancer patients and 16 benign ovarian tumor patients. The most significantly and differentially expressed miRNA was then further examined in all serum samples using real-time polymerase chain reaction. Its expression was further analyzed in relationship with clinicopathological factors and patient survival.ResultsArray screening data showed that expression levels of serum miRNA-20a, miRNA-125b, miRNA-126, miRNA-355, and let-7c were significantly different between malignant and benign ovarian tumor patients. Subsequent real-time polymerase chain reaction results showed that serum miRNA-125b levels were significantly higher in epithelial ovarian cancer patients compared to benign controls. Moreover, serum miRNA-125b levels were significantly higher in ovarian cancer patients in early stages I and II, and in patients having no residual tumor following surgery, but were not associated with differentiation and histological types of ovarian cancer. Notably, the higher level of miR-125b was significantly positively correlated with progression-free survival (P= 0.035) and marginally, with overall survival (P =0.069).ConclusionsmiRNA-125b plays an important role in the pathogenesis and progression of epithelial ovarian cancer. Circulating miRNA-125b has the potential to become a novel biomarker for early diagnosis and prognosis prediction of epithelial ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document